Cargando…

Tocilizumab for severe COVID-19 pneumonia

Detalles Bibliográficos
Autores principales:	Mourad, Jean-Jacques, Azria, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431121/ https://www.ncbi.nlm.nih.gov/pubmed/32838324 http://dx.doi.org/10.1016/S2665-9913(20)30282-4

Ejemplares similares

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19 – Authors' reply
por: Hayem, Gilles, et al.
Publicado: (2020)

Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy
por: Ammirati, Enrico, et al.
Publicado: (2020)

“Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case–control study from a tertiary care hospital”
por: Barthwal, M. S., et al.
Publicado: (2023)

Tocilizumab in COVID-19: finding the optimal route and dose
por: Jain, Siddharth, et al.
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Neumann, Avidan U, et al.
Publicado: (2021)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19
por: Mastroianni, Fiore
Publicado: (2020)

Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Severe Hypoxemia in Early COVID-19 Pneumonia
por: Bhatia, Pradeep, et al.
Publicado: (2020)

Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
por: Chuang, Tzu-Yi, et al.
Publicado: (2021)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020)

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis
por: Roumier, Mathilde, et al.
Publicado: (2020)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
por: Gentile, Giorgio, et al.
Publicado: (2021)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
por: Alex, Ruth, et al.
Publicado: (2022)

Provision of holistic care after severe COVID-19 pneumonia
por: McPeake, Joanne, et al.
Publicado: (2021)

Is IL-6 the Right Target in COVID-19 Severe Pneumonia?
por: Blot, Mathieu, et al.
Publicado: (2021)

High-Dose Prophylactic Anticoagulation in Severe COVID-19 Pneumonia
por: Nadeem, Rashid, et al.
Publicado: (2021)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia
por: Elabbadi, Alexandre, et al.
Publicado: (2021)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
por: Salama, Carlos, et al.
Publicado: (2020)

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
por: Gokhale, Yojana, et al.
Publicado: (2020)

Provision of holistic care after severe COVID-19 pneumonia – Authors' reply
por: D'Cruz, Rebecca F, et al.
Publicado: (2021)

Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab
por: Adre, Lorenzo Abednego B, et al.
Publicado: (2023)

Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study
por: Weber, Brittany N, et al.
Publicado: (2021)

PREVOTELLA BIVIA BACTEREMIA POST TOCILIZUMAB IN A PATIENT WITH SEVERE COVID-19 PNEUMONIA
por: AIYANYOR, ALFRED, et al.
Publicado: (2021)

Successful treatment of severe COVID-19 pneumonia with tocilizumab: A series of three cases
por: Chochoł-Labun, Joanna, et al.
Publicado: (2021)

Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study
por: Rossi, Benjamin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p19p0eggt9kul9hr2lombh1cd5